Articles
Page 21 of 25
-
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P80
-
Analysis of cGMP signalling with transgenic mice expressing FRET-based cGMP sensors
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P76 -
The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P75 -
Endothelial GC-A can be a therapeutic target for metabolic syndrome
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P73 -
Receptor guanylyl cyclase B-mediated cGMP signalling controls axon bifurcation of cranial sensory ganglion neurons at the embryonic hindbrain
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P71 -
Differential regulation of platelet inhibition by cGMP- and cAMP-dependent protein kinases
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P69 -
Cardiac cGMP/cGMP-dependent protein kinase I signalling requires cysteine-rich LIM-only protein 4 (CRP4) to oppose angiotensin II induced hypertrophy and fibrosis
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P68 -
Krait natriuretic peptide (KNP): a non-classical NP
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P67 -
Discovery of neuroprotective soluble guanylate cyclase modulators (GCMs) aciting via NO/GC/cGMP/CREB pathway
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P65 -
Function of cGMP-dependent protein kinase II in volume expansion-induced diuresis
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P63 -
Fishing for elusive cCMP-degrading phosphodiesterases
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P62 -
Suppression of kidney fibrosis by cGMP-dependent protein kinase I
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P61 -
In striatum phosphodiesterase 10A is part of a synaptic signalling complex
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P59 -
Soluble guanylyl cyclase mediates concomitant coronary vasodilator and positive inotropic actions of the HNO donor Angeli's salt in the intact rat heart
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P57 -
Potent inhibition of nitroglycerin bioactivation by diphenyleneiodonium (DIP)
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P49 -
Evidence for functional coupling of cGMP/cGKI signalling and TRPC channels in endothelium but not in vascular smooth muscle
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P40 -
Differential effects of PDE5 inhibitors on cardiac dysfunction in the MDX ouse model of Duchenne muscular dystrophy
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O38 -
A biodegradable in-situ polymer precipitation delivery system for sustained delivery of a novel chimeric natriuretic peptide CD-NP in an experimental model of myocardial infarction
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P38 -
Increases survival by apo-sGC activation via post-stroke blood brain barrier stabilisation and anti-inflammation
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P36 -
Dual actions of ANP on endothelial permeability
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O35 -
A bone overgrowth disorder due to a gain-of-function mutation in the kinase homology domain of guanylyl cyclase B, the receptor for CNP
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P35 -
A novel physiological significance of natriuretic peptides in cancer metastasis
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O34 -
Crystal structures of the carboxyl cGMP binding domain of plasmodium falciparumcGMP-dependent protein kinase reveals a novel salt bridge crucial for activation
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P33 -
NO-H2S interactions involve cGMP
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O32 -
Phosphodiesterase 5 is main regulator of brown adipocyte differentiation
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P32 -
Cyclic GMP-mediated intercellular communication in mammalian ovarian follicles
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P31 -
GUCY2C at the intersection of obesity and colorectal cancer
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O28 -
The role of VASP in cGMP-mediated vascular smooth muscle relaxation
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P28 -
PDE3 is the major cGMP-PDE in adult mouse ventricular cardiomyocytes
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P26 -
Natriuretic peptides and fat metabolism
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O24 -
Guanylyl cyclase-B plays an important role in adipogenesis and “browning” of white fat
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P24 -
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P23 -
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P22 -
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P21 -
New mechanisms of normoxic and hypoxic cGMP signalling mediated by the nitrite anion
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O20 -
Mechanisms driving heme insertion into apo-sGC during its maturation in cells
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O18 -
The soluble guanylyl cyclase activator BAY 60-2770 ameliorates detrusor dysfunction in obese mice
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P18 -
Receptor guanylyl cyclase-G is a novel thermosensor in Grueneberg ganglion neurons involved in coolness-induced ultrasonic distress calls in mice
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P14 -
Identification and quantitation of 2´,3´-cGMP in murine tissues
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P12 -
G-protein signaling modulator 1 is a modifier of sGC-dependent vascular response
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P11 -
MicroRNA miR-425 is a negative regulator of atrial natriuretic peptide
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O10 -
Pulmonary vascular adaptation to high-altitude living
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O9 -
Genetic variants of ANP and cardiometabolic protection: from populations to novel therapeutics
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O7 -
Effects of omeprazole and AlOH/MgOH on riociguat absorption
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P6 -
What have genome-wide association studies taught us about cGMP and blood pressure regulation?
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O5 -
Abstract not submitted for publication
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O3 -
Hydroxyurea reduces leukocyte interactions with the vessel wall in a haemolytic mouse model via a possible NO/cGMP-mediated effect
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P2 -
Increased nitrosative/oxidative stress lowers myocardial protein kinase G activity in heart failure with preserved ejection fraction
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O2 -
Neutral endopeptidase inhibitors SOL-1 and candoxatril counteract kidney fibrosis by reducing myofibroblast formation in mouse UUO model
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P1 -
Chronic natriuretic peptide protein therapeutics
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O1
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 2.8
5-year Journal Impact Factor: 2.8
Source Normalized Impact per Paper (SNIP): 0.774
SCImago Journal Rank (SJR): 0.710
Speed 2023
Submission to first editorial decision (median days): 25
Submission to acceptance (median days): 178
Usage 2023
Downloads: 790,731
Altmetric mentions: 400
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication